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Sudden cardiac arrest is most often the first clinical manifestation of an underlying cardiovascular disease and usually occurs in previously
asymptomatic athletes. The risk benefit ratio of physical exercise differs between young competitive athletes and middle-age/senior
individuals engaged in leisure-time sports activity. Competitive sports are associated with an increase in the risk of sudden cardiovascular
death (SCD) in susceptible adolescents and young adults with underlying cardiovascular disorders. In middle-age/older individuals, physical
activity can be regarded as a ‘two-edged sword’: vigorous exertion increases the incidence of acute coronary events in those who did not
exercise regularly, whereas habitual physical activity reduces the overall risk of myocardial infarction and SCD. Although cardiovascular pre-
participation evaluation offers the potential to identify athletes with life-threatening cardiovascular abnormalities before onset of symptoms
and may reduce their risk of SCD, there is a significant debate among cardiologists about efficacy, impact of false-positive results and cost-
effectiveness of routine screening. This review presents an appraisal of the available data and criticisms concerning screening programmes
aimed to prevent SCD of either young competitive athletes or older individuals engaged in leisure-time sports activity.
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Introduction
Regular physical exercise is recommended by the medical commu-
nity because it is associated with a decrease in all cause-mortality,
particularly from cardiovascular causes.1 Several epidemiological
and clinical studies have provided solid scientific evidence that
habitual aerobic physical activity reduces the risk of acute myocar-
dial infarction and sudden cardiac death (SCD).2 On the other
hand, vigorous exertion may acutely and transiently increase the
risk of acute coronary events and sudden cardiac arrest in suscep-
tible individuals.3 –5 For centuries, it was a mystery why SCD
should occur in athletes, who had previously achieved extraordi-
nary exercise performance without complaining of any symptoms.
It is now clear that the most common mechanism of SCD during
sports activity is an abrupt ventricular tachyarrhythmia as a
consequence of a wide spectrum of cardiovascular diseases.3– 10
The culprit disease is often clinically silent and unlikely to be sus-
pected or diagnosed on the basis of spontaneous symptoms of
the athlete. Systematic pre-participation screening of all subjects
embarking in sports activity has the potential to identify those ath-
letes at risk and to reduce mortality.11,12 There is, however, a sig-
nificant debate among cardiologists in Europe and the USA about
the efficacy, the impact of false-positive results, and cost-
effectiveness of routine pre-participation cardiovascular evaluation
of athletes.13,14
This article presents an appraisal of the available data and criti-
cisms concerning pre-participation screening programmes with the
target of reducing the cardiovascular risk of either competitive ath-
letes or individuals engaged in leisure-time sports activity. For the
purpose of the article, leisure athletes are defined in opposition to
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competitive athletes. According to Maron et al.,15 a competitive
athlete is a young (usually ≤35 years) subject who participates in
an organized team or individual sport that requires systematic
training and regular competition against others and that places a
high premium on athletic excellence and achievement. Conversely,
leisure athletes are individuals, most frequently middle-aged/senior
(usually .35 years), participating in a variety of informal rec-
reational sports, within a range of exercise levels from modest
to vigorous, on either a regular or an inconsistent basis, which
do not require systematic training or the pursuit of excellence.
Because leisure-time athletes may be involved in physical
activity—either for intensity or duration—not unlike competitive
athletes, this classification may be useless in individuals with cardi-
ovascular disorders, in whom risk assessment and sports eligibility
mainly depends on the athletic performance. However, the distinc-
tion between young competitive vs. middle-aged/senior leisure athletes
herein appears appropriate to address the available data on screen-
ing efficacy and cost-effectiveness, which mostly differ in relation to
age-related heart diseases.
Risk of sudden death in the athlete
The risk of SCD varies in the different athletes series reported in
the literature. It generally increases with age and is greater in
men.8– 10 In apparently healthy adults (.35 years), joggers, or
marathon racers, the estimated rate of SCD ranges from
1:15,000 to 1:50,000.3,4,10,16 In comparison, a significantly lower
incidence of fatal events have been reported in young
(≤35 years) competitive athletes (YCAs). A prospective study in
Italy showed an annual incidence of SCD of 3 per 100,000
YCAs,9 whereas the prevalence of fatalities among US high-school
and college athletes has been estimated to be ,1 in 100,000 par-
ticipants per year.17– 19 Compared with US high school and college
participants, the Italian athletic population includes older athletes
(age range 12–35 vs. 12–24 years) and a significantly higher pro-
portion of men (85 vs. 65%). This partly explains why the mortality
rates found in the Italian investigations are significantly higher than
those reported in the USA. In addition, while the Italian data were
systematically gathered from a well-defined geographic area (the
Veneto region of Italy) according to a prospective study design,
the US SCD rates were mostly based on retrospective analysis
of data from public media reports and insurance claims, which una-
voidably led to an incorrectly low number of events and underes-
timation of mortality. The accuracy of the determination of
incidence rates of SCD among US athletes is further questionable,
because denominator data did not reflect the real number of active
athletes in each year, but the total participation figures divided by
an estimate of the average number of sports, in which each high
school and college athlete participated.17– 19 Other studies with
more rigorous data collection and denominator estimates
reported an incidence of either SCD or sudden cardiac arrest of
young athletes in the USA quite similar to the incidences found
in the Veneto region of Italy in the pre-screening period
(Table 1).12,20–22
Atherosclerotic coronary artery disease accounts for the vast
majority of fatalities in adults (.35 years) (Figure 1), while the most
common causes of SCD in younger athletes are genetic or
congenital cardiovascular abnormalities, including cardiomyopathies
and coronary artery anomalies (Figure 2). Hypertrophic cardiomyopa-
thy (HCM) has been reported to account for more than one-third of
fatal cases in the USA,8,17,19 and arrhythmogenic right ventricular car-
diomyopathy (ARVC) for approximately one-fourth in the Veneto
Region of Italy.6,7,9,11,12 Two to five per cent of young people and ath-
letes who die suddenly have no evidence of structural heart disease
and the cause of their cardiac arrest in all likelihood is related to a
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Table 1 Incidence of sudden cardiac death/arrest in
young people and athletes according to different
reporting systems
Study
population
Ref. Study design and
reporting system
Incidence
(person-years)
US Military
(age 18–35)
Eckart
et al.21
Retrospective,
mandatory
1:9000
Italian Athletes
(age 12–35)
Corrado
et al.10
Prospective,
mandatory
1:25,000
US Adolescents
(age 12–19)
Atkins
et al.20
Prospective, EMS 1:27,000
US Children
(age 10–14)
Chugh
et al.22
Prospective, EMS/
Hospitals
1:58,000
US Athletes
(age 12–35)
Maron
et al.19
Retrospective,
public media
reports
1:160,000
EMS, emergency medical service.
Figure 1 Sudden death of a middle-aged athlete. Obstructive
atherosclerotic coronary artery disease of both left (anterior des-
cending branch) and right coronary arteries (A and B). Histology
of the myocardium shows replacement type fibrosis due to pre-
vious myocardial infarction (C ). Heidenhain trichrome.
Pre-participation athletic screening 935
primary electrical heart disease such as inherited cardiac ion channel
defects (channelopathies), including long and short QT syndromes,
Brugada syndrome, and catecholaminergic polymorphic ventricular
tachycardia.23 Sudden death may also be caused by a non-arrhythmic
mechanism—e.g., spontaneous aortic rupture complicating Marfan’s
syndrome or bicuspid aortic valve as well was by diseases not
related to the heart—e.g., bronchial asthma or rupture of a cerebral
aneurysm.2 Blunt, non-penetrating, and often innocently appearing
blows to the precordium may trigger ventricular fibrillation without
structural injury to ribs, sternum, or heart itself (commotio cordis).8
The risk-benefit ratio of physical exercise differs between adults
and YCAs because of the different nature of cardiovascular causes
of death.2,3,10 Several epidemiological studies have assessed the
relationship between physical exercise and the risk of acute myo-
cardial infarction/SCD in the middle-aged/senior individuals
engaged in leisure sports activity, in which physical exercise can
be regarded as a ‘two-edged sword’.1– 3,5,10 The available evidence
indicates that vigorous exercise acutely increases the incidence of
both cardiac arrest and acute myocardial infarction in those who
do not exercise regularly. In comparison, epidemiological studies
support the concept that habitual sports activity may offer pro-
tection against cardiovascular events over the long-term.1– 3,10
Adolescent and young adults involved in competitive sports activity
have an estimated risk of SCD approximately three times greater
than that of their non-athletic counterpart.9,12 Sports activity acts
as a trigger of arrhythmic cardiac arrest in those athletes with
predisposing cardiovascular conditions.
Sudden cardiac death shows a clear gender predilection with
striking male predominance (male to female ratio up to 10:1).9
This predominance of fatal events in male athletes has been tra-
ditionally explained because females participate less commonly in
competitive sports programmes than males. On the other hand,
Figure 2 Leading causes of sudden cardiovascular death in young competitive athletes. (A) Hypertrophic cardiomyopathy: short-axis cut of
the heart specimen showing asymmetric septal hypertrophy with multiple septal scars (top); histology of the interventricular septum revealing
typical myocardial disarray with interstitial fibrosis (bottom) (Heidenhain trichrome); (B) Arrhythmogenic right ventricular cardiomyopathy:
section of the heart specimen along the right ventricular infundibulum (left); panoramic histological view of the right infundibular free wall
showing wall thinning with fibro-fatty replacement (right) (Heidenhain trichrome); (C) Atherosclerotic coronary artery disease: histology of
the proximal tract of the left anterior descending coronary artery showing a non-obstructive fibrous plaque complicated by luminal thrombosis
due to endothelial erosion (Heidenhain trichrome); (D) Congenital coronary anomaly: gross view of the aortic root showing both coronary
ostia located in the right coronary sinus, with left coronary artery arising from the right aortic sinus of Valsalva and running between the
aorta and the pulmonary trunk.
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males have a higher prevalence and/or greater phenotypic
expression of potentially ‘lethal’ cardiovascular diseases, such as
HCM, ARVC, and premature coronary artery disease in the age
range of competitive sports.8,9,11
Pre-participation screening of
competitive athletes
The primary purpose of pre-participation screening is to identify
the cohort of athletes affected by unsuspected cardiovascular dis-
eases and to prevent SCD during sports by appropriate interven-
tions.13,25 The American College of Cardiology (ACC) states that
the ultimate goal of athletic screening is the detection of silent car-
diovascular abnormalities that can lead to SCD.25 Thus, from a
screening perspective, the prevalence of cardiovascular conditions
with the potential for SCD among adolescents and young adults is
of the utmost important. In contrast to the disparities on SCD
rates, the overall prevalence of cardiovascular diseases that predis-
pose to SCD in young athletes has been estimated to range from
0.2 to 0.7% (Table 2).12,26– 28
The vast majority of ‘at risk-athletes’ does not experience pre-
monitory symptoms and, thus, pre-participation screening rep-
resents the only strategy capable of identifying the underlying
cardiovascular disorder.13,25 The importance of early identification
of clinically silent cardiovascular diseases at a pre-symptomatic
stage relies on the concrete possibility of SCD prevention by life-
style modification, including restriction of competitive sports
activity (if necessary), but also by prophylactic treatment with
drugs and implantable defibrillator.25
Both the American Heart Association (AHA) and the European
Society of Cardiology (ESC) consensus panel recommendations
agree that cardiovascular screening for YCAs is justifiable and com-
pelling on ethical, legal, and medical grounds13,14. However, there
is a considerable discordance in the consensus guidelines on the
pre-participation screening protocols used among European and
US cardiologists/sports medicine physicians.
ECG screening
The AHA recommends pre-participation cardiovascular evaluation
by means of history (personal and family history) and physical
examination alone, although this screening protocol has a recog-
nized limited power (,10%) to detect potentially lethal cardiovas-
cular abnormalities.14 Glover and Maron29 found that of 134 high
school and collegiate athletes who suffered from SCD after they
underwent a pre-participation screening, only 3% were suspected
of having cardiac disease and, eventually, ,1% received an accu-
rate diagnosis. Twelve-lead ECG enhances the sensitivity of the
screening process by allowing early detection of cardiovascular
conditions distinctively manifesting with ECG abnormalities, such
as cardiomyopathies, pre-excitation syndromes, and cardiac ion
channel disorders13,25 (Table 3). Based on published series from
the USA and Italy, these ECG detectable conditions are present
in approximately two-thirds of YCAs with SCD.
Italy is the only country in the world where law mandates that
every subject engaged in competitive sports activity must
undergo a clinical evaluation to obtain eligibility.11,12 A nationwide
mass pre-participation screening programme, essentially based on
ECG, has been in practice since 1982 (Figure 3).12
The efficacy of ECG screening in the identification of cardio-
myopathies has been demonstrated in a large population-based
prospective study in the Veneto region of Italy.11,12 Among
33,735 athletes undergoing ECG screening at the Center for
Sports Medicine in Padua, 22 (0.07%) were identified with HCM,
based predominantly on an abnormal ECG.11 An absolute value
of ECG screening sensitivity for HCM cannot be derived from
this study because systematic echocardiographic findings were
not available; however, this 0.07% prevalence of HCM is similar
to that (0.10%) observed in a population-based study in the
USA, using echocardiography.30 This indicates that an ECG may
be as sensitive as an echocardiogram in detecting HCM in the
young athletic population. It is noteworthy that among the 22 ath-
letes with HCM who were detected by ECG screening, only 5
(23%) would had been identified on the basis of a positive
medical history or abnormal physical findings alone. Thus, the esti-
mated sensitivity of ECG screening for HCM is 77% greater than
that of a screening protocol which does not include the ECG.11
A recent US study on 510 student athletes showed that the
addition of ECG to history and physical examination improved
the detection of echocardiographically documented cardiac
abnormalities from 5 to 10 of 11, thereby improving the overall
sensitivity to 90.9%.31 Instead, the addition of an echocardiogram
to the basal protocol does not seem to significantly improve the
accuracy of ECG screening in identifying HCM.32
Impact on mortality
A subsequent Italian study provided the most compelling evidence of
efficacy of ECG screening to save lives by identifying and disqualifying
athletes with at-risk heart diseases. A time-trend analysis of the inci-
dence of SCD in YCAs in the Veneto region of Italy over 26 years
(1979–2004) showed a sharp decline of mortality rates after the
introduction of the nationwide screening programme.12 Fifty-five
SCDs occurred in screened athletes (1.9 deaths per 100,000 person-
years) and 265 deaths in unscreened non-athletes (0.79 deaths per
100,000 person-years). The annual incidence of SCD in athletes
decreased by 89%, from 3.6 per 100,000 person-years in the pre-
screening period to 0.4 per 100,000 person-years in the late-screening
period (Figure 4).
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Table 2 Prevalence of cardiovascular diseases at risk
for sudden cardiovascular death in young athletes
Ref. Population Prevalence
(%)
Fuller et al.26 5617 high school athletes (USA) 0.4
Corrado
et al.12
42,386 athletes age 12–35 (Italy) 0.2
Wilson
et al.27
2720 athletes and children age
10–17 (UK)
0.3
Bessem
et al.28
428 athletes age 12–35
(Netherlands)
0.7
Baggish
et al.31
510 collegiate athletes (USA) 0.6
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Table 3 ECG features of cardiac diseases detectable at pre-participation screening in young competitive athletes
Disease QTc interval P-wave PR interval QRS complex ST interval T-wave Arrhythmias
Hypertrophic
cardiomyopathy
Normal (left atrial
enlargement)
Normal Increased voltages in mid-left precordial
leads; abnormal ‘q’ waves in inferior
and/or lateral leads; (LAD, LBBB);
(delta wave)
Down-sloping
(up-sloping)
Inverted in mid-
left-precordial
leads; (giant and
negative in the
‘apical’ variant)
(atrial fibrillation); (PVB); (VT)
Arrhythmogenic right
ventricular
cardiomyopathy/
dysplasia
Normal Normal Normal Prolonged .110 ms in right precordial
leads; epsilon wave in right precordial
leads; reduced voltages ≤0.5 mV in
frontal leads; (RBBB)
(up-sloping in right
precordial
leads)
Inverted in right
precordial leads
PVB with a LBBB pattern;
(VT with a LBBB pattern)
Dilated cardiomyopathy Normal (left atrial
enlargement)
(prolonged
≥0.21 s)
LBBB Down-sloping
(up-sloping)
Inverted in inferior
and/or lateral
leads
PVB; (VT)
Myocarditis (prolonged) Normal Prolonged ≥0.21 s (abnormal ‘q’ waves) Down- or
up-sloping
Inverted in ≥2
leads
(atrial arrhythmias); (PVB);
(2nd or 3rd degree AV
block); (VT)
Long QT syndrome Prolonged .440 ms
in males; .460 ms
in females
Normal Normal Normal Normal Bifid or biphasic in
all leads
(PVB); (torsade de pointes)
Brugada syndrome Normal Prolonged ≥0.21 s S1S2S3 pattern; (RBBB/LAD) Up-sloping
‘coved-type’ in
right precordial
leads
Inverted in right
precordial leads
(polymorphic VT); (atrial
fibrillation) (sinus
bradycardia)
Lene`gre disease Normal Normal Prolonged ≥0.21 s RBBB; RBBB/LAD; LBBB Normal Secondary changes (2nd or 3rd degree AV block)
Short QT syndrome Shortened ,300 ms Normal Normal Normal Normal Normal Atrial fibrillation
(polymorphic VT)
Preexcitation syndrome
(WPW)
Normal Normal Shortened
,0.12 s
Delta wave Secondary
changes
Secondary changes Supraventricular tachycardia;
(atrial fibrillation)
Coronary artery diseases (prolonged) Normal Normal (abnormal ‘q’ waves) (down- or
up-sloping)
Inverted in ≥2
leads
PVB; (VT)
Less common or uncommon ECG findings are reported in brackets; coronary artery diseases, either premature coronary atherosclerosis or congenital coronary anomalies; QTc, QT interval corrected for heart rate by Bazett’s formula; LBBB,
left bundle branch block; RBBB, right bundle branch block; LAD,. left-axis deviation of 2308 or more; PVB, either single or coupled premature ventricular beats; VT , either non-sustained or sustained ventricular tachycardia. Adapted from
Corrado et al.13 D
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These data have generated a number of concerns.33,34 The main
criticism is that the study was not a randomized trial comparing
screening vs. non-screening of YCAs, and, thus, definitive con-
clusions that the reduced mortality was solely the consequence of
the screening process could not be drawn. However, the strong
cause–effect relationship between ECG screening and the substan-
tial reduction of SCD in this prospective, population-based investi-
gation is supported by the following findings: (i) there was a
coincident timing between decline of SCD in YCAs and screening
implementation in Italy; (ii) most of the reduced incidence of SCD
was due to fewer deaths from cardiomyopathies (HCM and
ARVC), and it was accompanied by the concomitant increase in
the proportion of YCAs who were identified with these cardiomyo-
pathies and disqualified from competition at the Center for Sports
Medicine in Padua during the same time interval; and 3) during
the study period, the incidence of SCD did not change among the
unscreened non-athletic population of the Veneto region of the
same age range.12 Although additional factors—environmental,
socio-economic, or medical/surgical—may have contributed to
mortality reduction over the time, such factors are expected to
impact mortality similarly in screened athletes and unscreened non-
athletes, and hence are unlikely to explain the declining trend in
SCD selectively recorded in the screened athletic population.12
It has been reported that during the time interval 1993–2004 the
annual rate of SCD among screened Italian athletes was roughly
similar to that of unscreened US high school and college competitors
(0.87 vs. 0.93 per 100,000 athlete-years, respectively; P ¼ 0.88).19
Thus, it has been argued that SCD in YCAs is a low event-rate
phenomenon which is unlikely to be influenced by pre-participation
ECG screening. However, as discussed above in the ‘Risk of sudden
death in the athlete’ section, the two athletic populations were
clearly non-comparable with regard to age and gender, the Italian ath-
letes being much older and including more males. Moreover, the US
mortality rates were unavoidably underestimated because of the
lack of a reliable reporting system and the retrospective data collec-
tion mostly based on reviews of public media reports.19
False-positive results
Changes in the ECG of trained athletes usually develop as a con-
sequence of the heart’s adaptation to sustained physical exercise
(‘athlete’s heart’).2,34 There is a misconception that such physio-
logical ECG changes overlap significantly with ECG abnormalities
seen in cardiovascular diseases that cause SCD in the young.14,35
Therefore, the ECG has been traditionally considered to be a
poor screening test in the athlete, because of its presumed high
level of false-positive results.14,35 Several studies disprove this
general idea that ECG is a non-specific and non-cost-effective
test. Among 42,386 athletes initially screened by history, physical
examination, and ECG, 3914 (9%) had positive findings as to
require further examination, 879 (2%) were diagnosed with cardi-
ovascular disorders and 91 (0.2%) were ultimately disqualified due
to potentially lethal heart diseases.12 The percentage of false-
positive results, i.e., athletes with a normal heart but positive
screening findings, was 7% for all cardiovascular disorders and
8.8% for heart diseases at high risk of SCD during sports. Likewise,
ECG screening of highly trained competitive athletes in the UK was
associated with a rate of false-positive results of only 3.7%.28
On the other hand, recent data in black athletes have shown a
higher prevalence of ECG abnormalities, indicating a varying ECG
specificity among athletes of different ethnicity.36 An increase in
the accuracy of ECG screening is expected as new studies
Figure 3 Flow diagram illustrating the modality of pre-
participation cardiovascular screening recommended by the
European Society of Cardiology section of Sports Cardiology.
The screening modality is substantially based on the Italian proto-
col of pre-participation cardiovascular evaluation. First line exam-
ination includes family history, physical examination, and 12-lead
ECG; additional tests are requested only for subjects who have
positive findings at the initial evaluation. Athletes recognized to
be affected by cardiovascular conditions potentially responsible
for sudden death in association with exercise and sport partici-
pation are managed according to the available recommendations
for sports eligibility. The screening starts at the beginning of com-
petitive athletic activity, which for the majority of sports disci-
plines corresponds to an age of 12–14 years. Because the
phenotypic manifestations both ECG abnormalities and arrhyth-
mic substrates of most inherited heart diseases are age-
dependent and occur during adolescence or young adulthood,
screening of children is expected to have a low sensitivity for
detection of cardiomyopathies and cardiac ion channel diseases,
except for long QT syndrome. Of importance, there is the
need of repeating the screening on a regular basis every
1–2 years, mostly in teenagers, in order to timely identify
delayed phenotypic manifestations, disease progression, or sub-
strate worsening over the time. In Italy, screening for cardiac
disease is part of a more comprehensive medical evaluation that
includes a general clinical history, physical examination, orthopae-
dic examination, spirometry, and urinalysis. In addition, athletes
undergo a Montoye step test, which is limited to evaluation of
heart rate recovery after exercise, although it may occasionally
unmask effort-dependent arrhythmias. Exercise-induced ST-T
abnormalities are appropriately assessed by maximal exercise
testing, which is reserved to competitive athletes ≥35 years.
Angio/EMB, contrast angiography/endomyocardial biopsy; EPS,
electrophysiological study with programmed ventricular stimu-
lation; MRI, magnetic resonance imaging. Modified from Corrado
et al.13
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emerge and are translated into updated guidelines for ECG
interpretation in the athlete, like the recent recommendations of
the ESC Section of Sports Cardiology.37 The document provides
cardiologists and sports medicine physicians to distinguish
between physiological and potentially pathological ECG patterns.
Defining which ECG changes are physiological (common and
training-related ECG abnormalities) and which are pathological
(uncommon and training-unrelated ECG abnormalities) (Figure 5)
has significant favourable effects on the athlete’s cardiovascular
management, including clinical diagnosis, risk stratification, and
cost savings. The effect of the use of the proposed modern criteria
is to substantially increase the ECG specificity (by 70%), primarily
in the important group of athletes who exhibit pure voltage criteria
for left ventricular hypertrophy and early repolarization abnormal-
ities, but with the important requisite of maintaining sensitivity for
detection of cardiovascular diseases predisposing to SCD during
sports.
Costs of screening
Unlike older patients with coronary artery diseases or heart failure,
young athletes/patients with a genetic disease at risk of SCD are
likely to survive for many decades with normal or nearly normal
life expectancy if detected by pre-participation cardiovascular
evaluation, thanks to restriction from competition and prophylactic
therapy against life-threatening arrhythmias.11,13,25,38 This large
amount of life-years saved favourably influences analysis of cost-
effectiveness of the screening process, with cost estimates per
year of life saved consistently below $50,000,39– 41 which is the tra-
ditional threshold to consider a health intervention as cost-
effective. A recent US analysis estimated that adding ECG to
history and physical examination in the screening protocol of ath-
letes aged 14–22 years saves 2.06 life-years per 1000 athletes, at a
cost of $42,000 per life-year saved.41
The benefit of pre-participation evaluation goes beyond the
detection of index athletes with an inherited heart disease
because it enables cascade screening of relatives, which results in
a multiplier effect for identifying other affected family members,
thus saving additional lives.25,38
Strategies for implementing nationwide screening programmes
depend on the particular socio-economic and cultural background
as well as on the specific medical systems in the different countries.
In Italy, screening is feasible thanks to the National Health System,
which has been developed in terms of healthcare and prevention
services, and to the limited costs of cardiovascular evaluation in
the setting of a mass-programme.13 The cost of performing a pre-
participation cardiac history, physical examination, and ECG by
qualified physicians has been estimated to be 30E. The costs
of screening are covered by the athlete or by the athletic team,
except for athletes ,18 years, for whom the expense is supported
by the National Health System. Moreover, the cost of further
evaluation of athletes with positive findings at first-line examination
is less than expected on the basis of the presumed low specificity of
athlete’s ECG. The percentage of athletes requiring additional
testing, mainly echocardiography, has been found to be 9%,
with a modest proportional impact on cost.11,12
Cost for developing the necessary infrastructure and for training
of specialized physicians should also be taken into account when-
ever calculating the overall screening cost. In Italy, those physicians,
who are primarily responsible for ECG screening and eligibility for
competitive sports, attend postgraduate residency training pro-
grammes in sports medicine (and sports cardiology) for 4 years
(‘full-time’). Such specialists work in sports medical centres, specifi-
cally devoted to periodical evaluation of athletes.
Individual cost
Disqualification from competition of a young athlete diagnosed
with a heart disease may be associated with important individual
Figure 4 Annual incidence rates of sudden cardiovascular death per 100,000 person, among screened competitive athletes and unscreened
non-athletes 12–35 years of age in the Veneto Region of Italy, from 1979 to 2004. During the study period (the nationwide pre-participation
screening programme was initiated in 1982), the annual incidence of sudden cardiovascular death declined by 89% in screened athletes (P for
trend ,0.001). In contrast, the incidence of sudden cardiovascular death did not demonstrate consistent changes over that time in unscreened
non-athletes. Modified form Corrado et al.12
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costs in terms of health, contentment, and even future opportunity
for professional sports. The risk of SCD during sports inherent to
many cardiovascular disorders is still unknown, difficult to assess,
and relatively low. A number of disqualified athletes would not
die or experience any other consequences due to their physical
activity. The screening perspective, however, is that the risk of
SCD associated with competitive sports in the setting of poten-
tially life-threatening cardiovascular disease is a controllable
factor, and the devastating impact of even infrequent fatal events
in the young athletic population justifies appropriate restriction
from competition.25,26
Screening athletes for cardiomyopathies and ion channel disorders
is expected to be most productive in preventing athletic-field SCD,
while the exclusion from competition of other young athletes with
non-lethal diseases is more arbitrary and likely not as productive.13,25
The prevalence of Italian athletes who were diagnosed and disquali-
fied because of cardiovascular diseases was 2%; however, true
potentially lethal conditions, such as cardiomyopathies, rhythm and
conduction disturbances, long QT syndrome, valvular heart
disease, coronary artery disease, and Marfan syndrome were ident-
ified in a smaller subgroup not exceeding 0.2%12 (Table 3). This has
significant implications for optimizing sports eligibility guidelines and
management of YCAs with cardiovascular diseases in the future. The
main objective should be to reduce the number of unnecessary dis-
qualifications and to adapt (rather than restrict) sports activity in
relation to the specific cardiovascular risk.
Other preventive strategies
The screening ability to detect YCAs with either premature coron-
ary atherosclerosis or congenital coronary anomalies is limited by
the scarcity of baseline ECG signs of myocardial ischaemia.11,13,25,42
Moreover, SCD during sports may be the result of non-penetrating
chest injury (commotio cordis) which cannot be prevented by
screening.8 This justifies the growing efforts to implement
additional prevention strategy based on early external defibrillation
of sudden cardiac arrest.43 The presence of a free-standing auto-
mated external defibrillator (AED) at sporting events may be a
valuable intervention for conditions unrecognized by screening.
However, AED should not be considered neither as a substitute
of pre-participation evaluation nor a justification for participation
in competitive sports of athletes with at risk-heart diseases.
Chances for on-field successful resuscitation are remote, even if
cardiopulmonary resuscitation is started immediately and defibrilla-
tion equipment is readily available. Drezner et al.44 reported that
only 11% of athletes with underlying cardiomyopathy survived
from athletic-field cardiac arrest despite a witnessed collapse,
timely cardiopulmonary resuscitation, and prompt defibrillation.
Pre-participation screening of
leisure athletes
The risk of sports-related acute cardiovascular events, including
SCD, increases exponentially among individuals .35 years and is
almost exclusively related to the development and progression of
atherosclerotic coronary artery disease.10 The growing number of
middle-aged/senior subjects engaged in leisure-time sports activity,
outside the competitive sports community, makes the pre-
participation screening of this athletic population an emerging task,
with specific problems in terms of feasibility, logistics, and costs.
The identification and management of coronary artery disease in
asymptomatic adults and elderly is a controversial issue. So far, no
strategies have been adequately studied to evaluate their ability to
reduce the risk of exercise-related acute cardiovascular events in
this group of athletes.2
Several epidemiological studies reported the association
between ECG abnormalities and an increased relative risk (1.5–
2.5 fold) of mortality from coronary artery disease.45,46 Despite
its recognized prognostic value, the utility of ECG for screening
asymptomatic subjects without known coronary atherosclerosis
is limited. Up to half of individuals with angiographically normal
coronary arteries show ECG changes, approximately one-third
of those with coronary artery disease show normal basal ECG
findings, and, most importantly, the vast majority of coronary
events occurs in the absence of prior ECG abnormalities.47,48
Figure 5 Classification of ECG abnormalities in the athlete.
Common ECG abnormalities: up to 80% of trained athletes
exhibit ECG changes such as sinus bradycardia, first degree AV
block, early repolarization, incomplete right bundle branch
block and pure increase of QRS voltages (Group 1). Such
common ECG changes are the consequence of the physiological
cardiovascular adaptation to sustained physical exertion and do
not reflect the presence of an underlying cardiovascular
disease. Therefore, they are not associated with an increase in
cardiovascular risk and allow eligibility to competitive sports
without additional evaluation. Uncommon ECG abnormalities: this
subset includes uncommon ECG patterns (,5%) such as
ST-segment and T-wave repolarization abnormalities, pathologi-
cal Q-waves, intraventricular conduction defects, and ventricular
arrhythmias (Group 2). These ECG abnormalities are unrelated to
athletic conditioning and should be regarded as an expression of
possible underlying cardiovascular disorders, notably cardiomyo-
pathies and cardiac ion channel diseases, and, thus, associated
with an inherent increased risk of sudden arrhythmic death. AV,
atrioventricular; RBBB, right bundle branch block; LBBB, left
bundle branch block. Modified form Corrado et al.37
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Thus, basal ECG results in an unacceptably large number of false-
negative and false-positive results in athletes .35 years and is not
suitable as a single test for screening this athlete’s age-group.
Exercise testing screening
Because of its established prognostic value, widespread availability
and low cost, exercise testing is widely deemed the best available
test for screening asymptomatic adults prior to an exercise pro-
gramme. Several studies reported an increase in the relative risk
of coronary death (range 2–5), for those asymptomatic subjects
with a positive exercise testing.49–51 However, the test accuracy
for detection of coronary artery disease is expectedly limited
among the general population because of the relatively low dis-
ease’s prevalence.52,53 The test performance increases with a
greater pre-test probability of coronary atherosclerosis, so that
subgroups of asymptomatic individuals with risk factors who
would most benefit from screening by exercise testing have been
defined.50,51,54 These subgroups include men with advanced age,
multiple coronary risk factors, or diabetes; instead, the test prog-
nostic value has not been demonstrated in asymptomatic healthy
women. There is evidence that the risk of cardiac events related
to underlying coronary artery disease further depends on the
level of fitness/habitual physical activity as well as on the intensity
of the intended physical exercise.55– 57 However, the predictive
value of exercise ECG test for cardiovascular events occurring
specifically during exercise is very limited. Siskovick et al.49
reported a 18% sensitivity and 92% specificity of a positive exercise
testing to predict an exercise-related cardiovascular event in
asymptomatic, hypercholesterolaemic men (35–59 years).
Although there are no solid scientific data to guide the use of
exercise testing for screening, several Associations of Cardiology
and Sports Medicine have addressed this important issue by con-
sensus.58–60 Despite slight differences, the common denominator
of current recommendations is that individuals who appear to be
at a greater risk of suffering from underlying coronary artery
disease (for instance those with diabetes mellitus61 –63) should
be considered for exercise testing prior to the beginning a vigorous
exercise training programme. In contrast, the US Preventive
Services Task Force states that there is insufficient evidence to
determine the benefits of pre-participation exercise testing prior
to exercise programmes.64
European Society of Cardiology
Recommendations
Most recent recommendations of cardiovascular evaluation of
middle-aged/senior individuals engaged in leisure sports activity
have been proposed by the ESC sections of Sports Cardiology
Figure 6 Specific pre-participation screening work-up for sedentary middle-aged/senior individuals. Sedentary individuals are defined as indi-
viduals whose energy expenditure during physical exercise accumulates to ,2 MET-h/week. This low activity has been associated with higher
coronary event rates and a poorer prognosis. The recommendations consider low cardio respiratory fitness equivalent of having a high risk
according to score. The intensity of the intended physical exercise programme, assessed by the individual or by a non-physician is classified
as follows:(i) low intensity, corresponding to 1.8–2.9 METS; (ii) moderate intensity, corresponding to 3–6 METS; (iii) high intensity, including
individuals participating/willing to participate in masters events such as long-distance cycling, city marathons, long distance cross country skiing
and triathlons, corresponding to an effort .6 METS.
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and Exercise Physiology of the European Association of Cardiovas-
cular Prevention and Rehabilitation.60 Figures 6 and 7 summarize
the specific work-up of cardiovascular evaluation recommended
as appropriate for either sedentary or regularly active individuals,
based on the individual risk profile and the type or intensity of
intended physical exercise.60 The recommended first line evalu-
ation consists of a self-assessment (by the individual or by non-
physician health-related professionals) of the habitual physical
activity level and the risk factors, using validated questionnaires
such as the AHA pre-participation Questionnaire65 or the
simpler revised Physical Activity Readiness Questionnaire.66 If indi-
cated, subsequent thorough risk assessment is performed by a qua-
lified physician, using the ESC Systematic Coronary Risk Evaluation
(SCORE).67– 69 According to the SCORE system, the assessment
of cardiovascular risk of coronary death within 10 years is based
on age, sex, blood pressure, blood cholesterol, and smoking
history.67– 69 Maximal exercise testing (and possibly further cardi-
ological evaluations) is reserved to those individuals embarking in
moderate/intense physical activity who show an increased risk
for coronary events.63
Whether further evaluation and successful treatment of an
asymptomatic individual with a positive exercise test by interven-
tional/non-interventional therapies can improve outcomes,
thereby validating the screening clinical utility, remains to be estab-
lished. Screening with exercise testing is likely to be cost-effective
in older patients with coronary risk factors, while it is not justified
in low-risk subgroups.
Conclusions
The available evidence, based on the long-running Italian experi-
ence, indicates that ECG screening has to be considered an effi-
cient health strategy for prevention of SCD of YCAs. It meets
the most important Wilson and Jungner’s criteria70 for appraising
the validity of a screening strategy: (i) safe sports activity represents
an important health issue; (ii) still asymptomatic athletes with at
risk-heart diseases are successfully identified; (iii) an effective man-
agement strategy based on restriction of life-threatening training/
competition and subsequent clinical treatment of at risk-athletes
does exist; (iv) and early identification/management of the under-
lying disease favourably modifies the outcome and leads to sub-
stantial mortality reduction.
It is noteworthy that a 25-year interval was required to gener-
ate the Italian data showing the actual success of the pre-
participation ECG screening programme. Until data from other
studies of comparable prospective study design, size of the
study athletic cohort, and follow-up duration are obtained, the
existing data provide good evidence that pre-participation screen-
ing does work. If one accepts the principle, sanctioned by both
the AHA and the ESC, that cardiovascular screening for YCAs
is justifiable and compelling, the available evidence suggests to
adopt a screening protocol including ECG, which is the only
screening tool proved to be effective. Hence, pre-participation
ECG screening of YCAs has been recommended by the ESC,13
by the International Olympic Committee (‘Lausanne
Figure 7 Specific pre-participation screening work-up for regularly active middle-aged/senior individuals. Active individuals are defined as
those accumulating ≥2 MET-h/week, even intensive, though non-competitive sport activities. Classification of intensity of the intended physical
activity as in Figure 6.
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Recommendations’),71 and by most European Cardiologic
Societies and Sports Medical Federations (Table 4).72
The AHA 2007 Update on pre-participation athletic screening
again recommends the traditional history/physical exam protocol
without ECG. Most importantly, the document does not dispute
the incremental value to ECG screening, but concludes that it is
not applicable to the US system because of the logistics, man-
power, and financial resources required for a national screening
programme.14
On the other hand, the utility of screening middle-aged/senior
individuals engaged in leisure sports by exercise testing to detect
coronary artery disease remains to be determined. This explains
the large discordance between the screening recommendations
and the lack of uniformity in clinical practice. Because many sports-
related SCDs occur in adult and elderly people, prevention by the
introduction of a feasible screening protocol remains a clinical
challenge. According to the guidelines of the ESC, ACC/AHA,
and the American College of Sports Medicine, exercise testing
screening prior to initiating a vigorous exercise training should
be reserved to those asymptomatic individuals with an increased
risk of coronary artery disease, assessed using available risk score
systems. Although this strategy has not been rigorously evaluated
to reduce exercise-related cardiovascular morbidity and mortality,
it appears to be prudent in the light of our current understanding
of the risks and benefits of exercise in this age group.
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Table 4 Pre-participation athletic screening of young competitive athletes in European countries
Country Medical/sports Associations Target athletic population Screening protocol
Luxemburg National Sports Ministry, Olympic
Medical Committee, National
Association of Sports Physicians
Competitive athletes of all sports History, physical examination, ECG
(required)
Sweden National Board of Health and Welfare,
National Federation of Sports
Elite athletes of all sports History, physical examination, ECG
(recommended)
Norway Norvegian Football Association Medical
Committee
Professional football players History, physical examination, ECG,
echocardiography (required)
Germany German Association of Sports Medicine,
National Sports Federations
Elite athletes of all sports History, physical examination, ECG,
echocardiography, exercise testing
(required)
Poland Ministry of Sports and Tourism, Ministry
of Health, Polish Cardiac Society,
Sports Federations
Competitive athletes (age ,23 years) of all
sports and national team members
History, physical examination, ECG
(required)
France National Sports Ministry Professional athletes of all sports History, physical examination, ECG,
echocardiography, exercise testing
(required)
French Society of Cardiology Competitive athletes of all sports History, physical examination, ECG
(recommended)
Scotland Government, Department of Health Football, competitive athletes .16 years old History, physical examination, ECG
(required)
England British Lawn Tennis and Football
Associations
Competitive athletes History, physical examination, ECG
(required)
Greece Hellenic College of Sports Medicine,
National Sports Federations
Competitive athletes of all sports History, physical examination, ECG
(recommended)
Belgium National Sports Federations Athletes of cycling and motocross sports History, physical examination, ECG
(required)
Spain High Sports Government Council Competitive athletes of all sports History, physical examination, ECG
(recommended)
The Netherlands Working group of Cardiovascular
Prevention and Rehabilitation,
National Olympic Committee,
National Sports Federations,
Netherland Society of Cardiology
Elite competitive athletes (age ,35 years) of
all sports
History, physical examination, ECG
(required)
Professional football players History, physical examination, ECG,
echocardiography (required)
Elite athletes of cycling, motor and flying
sports and diving
History, physical examination, ECG
(required)
Adapted from Corrado et al.72
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